Cipla announced record Q2 FY26 revenue of INR7,589 crores, a year-on-year growth of 8%. EBITDA margin stood at 25%. The company saw strong performance across One-India, U.S. Generics, One Africa, and EMEU. Cipla launched Yurpeak, entering the obesity care segment and is revising its full-year EBITDA margin guidance to 22.75% to 24%.
Financial Performance
Cipla reported record revenue for Q2 FY26, reaching INR7,589 crores, reflecting an 8% year-on-year growth. The EBITDA margin for the quarter was strong at 25%. Gross margin after material cost stood at 67%. Total expenses for the quarter were INR3,197 crores, an increase of 11% compared to the previous year. R&D investment for the quarter amounted to INR539 crores, or 7.1% of revenue. Profit after tax for the quarter stood at INR1,351 crores, representing 17.8% of sales.
Segmental Performance
One-India business showed improved growth with a 7% year-on-year increase. Key therapies demonstrated double-digit growth. The chronic mix strengthened to 61.8%. North America delivered revenue of $233 million, with Cipla becoming the number one player in the U.S. albuterol MDI market with a market share of 22%. The lanreotide market share rose to 22%. The company launched filgrastim, its first biosimilar in the U.S. market. One Africa recorded a growth of 5% year-on-year, with South Africa growing at 6%. The EMEU business delivered its strongest quarterly revenue at USD 110 million, a year-on-year growth of 15%.
Strategic Initiatives
Cipla is entering the obesity care segment with the launch of Yurpeak (tirzepatide). The company is expanding across multiple therapies through strategic introductions. Six new launches during the quarter enhanced its trade generics business. Key priorities include focusing on execution to regain growth momentum in One India and enhancing commercial execution in North America. U.S. FDA inspection for the Bommasandra facility qualified as VAI.
Revised Outlook
Following a review, Cipla revised its full-year EBITDA margin guidance to approximately 22.75% to 24%, excluding the Yurpeak business plan.
Source: BSE
